文献速递心力衰竭与心肌病血脂与心血管预防

恩格列净联合袢利尿剂对2型糖尿病合并心衰患者的肾脏和心血管效应:RECEDE-CHF试验

Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
PubMed 文献 · Circulation · 2020-08-29

主要终点24小时尿量在恩格列净组第3天和第6天均显著增加,但24小时尿钠无显著变化,第6天电解质自由水清除率显著增加,体重和血清尿酸显著降低。

要点

  • 恩格列净联合袢利尿剂可显著增加24小时尿量,但不增加尿钠排泄。
  • 恩格列净在第6天显著增加电解质自由水清除率,并降低体重和血清尿酸。
  • 该联合方案在2型糖尿病合并射血分数降低心衰患者中显示出利尿效应。

核心结论

  • 恩格列净与袢利尿剂联用时显著增加24小时尿量,但不增加尿钠排泄。

研究设计与样本

  • 患者随机接受恩格列净25 mg每日一次或安慰剂治疗6周,洗脱期2周。
  • 主要终点为从基线至第6周24小时尿量的变化。

主要发现

  • 与安慰剂相比,恩格列净使第3天24小时尿量平均差异增加535 mL(95%CI 133-936;P=0.005)。
  • 与安慰剂相比,恩格列净使第6周24小时尿量平均差异增加545 mL(95%CI 136-954;P=0.005)。
  • 第6周24小时尿钠平均差异为-7.85 mmol/L(95%CI -2.43至6.73;P=0.57),无显著变化。
  • 第6周电解质自由水清除率平均差异增加312 mL(95%CI 26-598;P=0.026)。
  • 恩格列净在第6周显著降低体重和血清尿酸。

临床怎么用

  • 对于2型糖尿病合并射血分数降低心衰且使用袢利尿剂的患者,恩格列净可增加尿量但不增加尿钠排泄。
  • 恩格列净联合袢利尿剂时可通过增加自由水清除发挥利尿效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SGLT2 (sodium-glucose cotransporter-2) inhibitors improve heart failure-associated outcomes in patients with type 2 diabetes. In patients with heart failure, SGLT2 inhibitors will likely be coprescribed with a loop diuretic, but this combined effect is not well-defined. Our aim was to assess the diuretic and natriuretic effect of empagliflozin in combination with loop diuretics. METHODS: The RECEDE-CHF trial (SGLT2 Inhibition in Combination With Diuretics in Heart Failure) was a randomized, double-blind, placebo-controlled, crossover trial of patients with type 2 diabetes and heart failure with reduced ejection fraction taking regular loop diuretic who were randomized to empagliflozin 25 mg once daily or placebo for 6 weeks with a 2-week washout period. The primary outcome was change in 24-hour urinary volume from baseline to week 6. RESULTS: Twenty-three participants (mean age, 69.8 years; 73.9% male; mean furosemide dose, 49.6±31.3 mg/d; mean HbA1c, 7.9±3.8%) were recruited. Compared with placebo, empagliflozin caused a significant increase in 24-hour urinary volume at both day 3 (mean difference, 535 mL [95% CI, 133-936]; P=0.005) and week 6 (mean difference, 545 mL [95% CI, 136-954]; P=0.005) after adjustment for treatment order, baseline 24-hour urine volume, and percentage change in loop diuretic dose. At 6 weeks, empagliflozin did not cause a significant change in 24-hour urinary sodium (mean difference, -7.85 mmol/L [95% CI, -2.43 to 6.73]; P=0.57). Empagliflozin caused a nonsignificant increase in fractional excretion of sodium at day 3, which was absent at week 6 (mean difference day 3, 0.30% [95% CI, -0.03 to 0.63]; P=0.09; week 6, 0.11% [95% CI, -0.22 to 0.44]; P>0.99), and a significant increase in electrolyte-free water clearance at week 6 (mean difference, 312 mL [95% CI, 26-598]; P=0.026) compared with placebo. Empagliflozin also caused significant reductions in body weight and serum urate at week 6. CONCLUSIONS: Empagliflozin caused a significant increase in 24-hour urine volume without an increase in urinary sodium when used in combination with loop diuretic. Registration: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT03226457.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Mordi NA, Mordi IR, Singh JS, et al. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial. Circulation. 2020. PMID: 32865004. doi:10.1161/CIRCULATIONAHA.120.048739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。